Page 74 - 50_Curso_Pneumologia

BIBLIOGRAFIA
1. Sequist LV, Neal JW : Personalized, genotype-directed therapy for advanced

non-small cell lung cancer. UpToDate, 2017
2. Moreira AL,Juliana E: Personalized Therapy for Lung Cancer . CHEST 2014;

146, 6

3. Chan BA; Hughes BGM: Targeted Therapy for Non-small Cell Lung Cancer:
Current Standards and the Promise of the Future. Transl Lung Cancer

Res. 2015;4(1):36-54.

4. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the Evolution of
Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376:2109.

5. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor
cells and circulating tumor DNA. Cancer Discov 2014; 4:650.

6. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective Validation of Rapid
Plasma Genotyping for the Detection of EGFR and KRAS Mutations in

Advanced Lung Cancer. JAMA Oncol 2016; 2:1014.

7. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology
study of EGFR mutations in Asian patients with advanced non-small-cell lung

cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9:154.
8. Oxnard GR, Thress KS, Alden RS, et al. Association Between Plasma

Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in
Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:3375.

9. Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of nonsmall

cell lung carcinomas with BRAF mutations. Ann Oncol 2014; 25:138.
10. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for

previously treated, PD-L1-positive, advanced non-small-cell lung cancer
(KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387:1540.